Proton pump inhibitor: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
imported>Robert Badgett |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
In [[medicine]], '''proton pump inhibitors''' ('''PPI''') are [[medication]]s that "inhibit H(+)-K(+)-exchanging atpase. They are used as [[anti-ulcer agent]]s and sometimes in place of [[histamine H2 antagonist]]s for [[gastroesophageal reflux]]."<ref>{{MeSH}}</ref> They are also used as part of curative [therapy for ''[[Helicobacter pylori]]'', in combination with [[antibiotic]]s. | In [[medicine]], '''proton pump inhibitors''' ('''PPI''') are [[medication]]s that "inhibit H(+)-K(+)-exchanging atpase. They are used as [[anti-ulcer agent]]s and sometimes in place of [[histamine H2 antagonist]]s for [[gastroesophageal reflux]]."<ref>{{MeSH}}</ref> They are also used as part of curative [therapy for ''[[Helicobacter pylori]]'', in combination with [[antibiotic]]s. | ||
==Metabolism== | |||
Proton pump inhibitors are metabolized by the CYP2C19 isoenzyme of [[cytochrome P-450]]. | |||
==Adverse effects== | ==Adverse effects== | ||
Proton pump inhibitors may be associated with [[spontaneous bacterial peritonitis]].<ref name="pmid19337238">{{cite journal |author=Bajaj JS, Zadvornova Y, Heuman DM, ''et al.'' |title=Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites |journal=Am. J. Gastroenterol. |volume=104 |issue=5 |pages=1130–4 |year=2009 |month=May |pmid=19337238 |doi=10.1038/ajg.2009.80 |url=http://dx.doi.org/10.1038/ajg.2009.80 |issn=}}</ref> These drugs may also be associated with [[pneumonia]], ''[[Clostridium difficile]]'' diarrhea, and [[fracture]]s. | |||
Proton pump inhibitors, which are metabolized by the CYP2C19 isoenzyme of [[cytochrome P-450]], may<ref name="pmid19258584">{{cite journal |author=Ho PM, Maddox TM, Wang L, ''et al.'' |title=Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome |journal=JAMA |volume=301 |issue=9 |pages=937–44 |year=2009 |month=March |pmid=19258584 |doi=10.1001/jama.2009.261 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=19258584 |issn=}}</ref> or may not<ref name="pmid19106083">{{cite journal |author=Simon T, Verstuyft C, Mary-Krause M, ''et al.'' |title=Genetic determinants of response to clopidogrel and cardiovascular events |journal=N. Engl. J. Med. |volume=360 |issue=4 |pages=363–75 |year=2009 |month=January |pmid=19106083 |doi=10.1056/NEJMoa0808227 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=19106083&promo=ONFLNS19 |issn=}}</ref> increase adverse cardiac events when given to patients taking [[clopidogrel]] for [[coronary heart disease]]. | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 10:10, 14 August 2009
In medicine, proton pump inhibitors (PPI) are medications that "inhibit H(+)-K(+)-exchanging atpase. They are used as anti-ulcer agents and sometimes in place of histamine H2 antagonists for gastroesophageal reflux."[1] They are also used as part of curative [therapy for Helicobacter pylori, in combination with antibiotics.
Metabolism
Proton pump inhibitors are metabolized by the CYP2C19 isoenzyme of cytochrome P-450.
Adverse effects
Proton pump inhibitors may be associated with spontaneous bacterial peritonitis.[2] These drugs may also be associated with pneumonia, Clostridium difficile diarrhea, and fractures.
Proton pump inhibitors, which are metabolized by the CYP2C19 isoenzyme of cytochrome P-450, may[3] or may not[4] increase adverse cardiac events when given to patients taking clopidogrel for coronary heart disease.
References
- ↑ Anonymous (2024), Proton pump inhibitor (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Bajaj JS, Zadvornova Y, Heuman DM, et al. (May 2009). "Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites". Am. J. Gastroenterol. 104 (5): 1130–4. DOI:10.1038/ajg.2009.80. PMID 19337238. Research Blogging.
- ↑ Ho PM, Maddox TM, Wang L, et al. (March 2009). "Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome". JAMA 301 (9): 937–44. DOI:10.1001/jama.2009.261. PMID 19258584. Research Blogging.
- ↑ Simon T, Verstuyft C, Mary-Krause M, et al. (January 2009). "Genetic determinants of response to clopidogrel and cardiovascular events". N. Engl. J. Med. 360 (4): 363–75. DOI:10.1056/NEJMoa0808227. PMID 19106083. Research Blogging.